A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Primary Purpose
Advanced or Metastatic Solid Tumors
Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
MRG004A
Sponsored by

About this trial
This is an interventional treatment trial for Advanced or Metastatic Solid Tumors focused on measuring MRG004A, Antibody drug conjugate (ADC), Tissue factor, Solid tumors
Eligibility Criteria
Inclusion Criteria:
- Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- Age ≥18 years.
- Life expectancy ≥6 months.
- For Part B patients, documented Tissue Factor (TF) presence in tumor biopsy specimens obtained from archival or re-biopsy specimens by immunohistochemistry (IHC) protein expression.
- Must have histologically or cytologically confirmed unresectable or metastatic cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types- Part A and Part B.
- Part B: Patients who have documented progression during or relapse following standard therapy, no further treatment options that are known to improve survival, and participation in a clinical trial is a reasonable therapeutic option.
- Patients must have measurable disease per RECIST v1.1.
- ECOG performance status of 0 or 1.
- Acceptable bone marrow, hepatic, cardiac, renal, and coagulation function.
- A negative serum pregnancy test if female and aged between 18-55 years old.
- Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 180 days after the last infusion of MRG004A.
Exclusion Criteria:
- Archival or biopsy tumor shows TF IHC membrane or cytosolic score of zero, no TF-positive expression or no TF-positive staining in Part B patients.
- Toxicities (except alopecia & fatigue) due to prior antitumor therapy are greater than CTCAE v5.0 Grade 1.
- Toxicities due to prior radiotherapy that have not resolved to Grade ≤ 1 CTCAE v5.0 at least 21 days prior to the first treatment.
- Untreated, unstable or uncontrolled central nervous system (CNS) metastases.
- Any other type of anti-cancer therapy within 21 days of the first dose of study treatment. Use of any other type of anti-cancer treatment is prohibited throughout the study.
- Patients with increased bleeding risk.
- Presence of severe cardiac dysfunction.
- Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.
- Concurrent malignancy within 5 years prior to entry.
- Uncontrolled or poorly controlled hypertension.
- History of ventricular tachycardia, or torsade des pointes.
- History of moderate to severe dyspnea at rest.
- Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
- Known allergic reactions to any component or excipient of MRG004A or known allergic reactions to other prior anti-TF (including investigational) or other monoclonal antibody ≥ Grade 3.
- Patients who have any known liver disease, including chronic hepatitis B, hepatitis C, autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis; Patients who have concurrent, serious, uncontrolled infections or known infection with HIV, or have a diagnosed acquired immunodeficiency syndrome (AIDS); or an uncontrolled autoimmune disease, or have undergone organ transplant.
- Active uncontrolled bacterial, viral, fungal, rickettsial, or parasitic infection.
- Use of systemic corticosteroids within 4 weeks prior to the first dose of treatment.
- Use of strong CYP3A4 inhibitors or inducers with MRG004A.
- Other excluded medications or treatment: therapeutic anti-coagulative, or long-term anti-platelet treatment; multivitamins, calcium, vitamin D, and prophylactic anti-RANKL (denosumab) and zoledronic acid therapies for bone metastases are allowed.
- Any patient with a positive pregnancy or is breast-feeding.
- Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.
Sites / Locations
- Chao Family Comprehensive Cancer CenterRecruiting
- Memorial Sloan Kettering 60th Street Outpatient CenterRecruiting
- Gabrail Cancer Center ResearchRecruiting
- The Christ Hospital Cancer CenterRecruiting
- Gettysburg Cancer CenterRecruiting
- Virginia Cancer SpecialistsRecruiting
- Hunan Cancer Hospital
- Fudan University Shanghai Cancer Center
- The First Affiliated Hospital, College of Medicine, Zhejiang University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MRG004A
Arm Description
All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
Outcomes
Primary Outcome Measures
Maximum Tolerated Dose (MTD)
The highest dose confirmed wherein less than 2 out of 6, or < 33% of evaluable patients in a treatment cohort experiences dose-limiting toxicity (DLT).
Recommended Phase II Dose (RP2D)
The dose level of MRG004A recommended for further clinical studies based on assessment of the safety, efficacy and PK data from Part A of this study.
Objective Response Rate (ORR)
The proportion of patients who achieve complete response (CR) or partial response (PR) as assessed by the Independent Central Review (ICR).
Adverse Events (AEs)
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
Secondary Outcome Measures
Duration of Response (DoR)
The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.
Disease Control Rate (DCR)
The proportion of patients who achieve CR, PR, or stable disease (SD) ≥ 6 weeks based on RECIST v1.1.
Progression Free Survival (PFS)
The time from the date of first study dose to disease progression or death whichever occurs first.
Overall Survive (OS)
The time from start of study treatment to date of death as a result of any cause.
Pharmacokinetics (PK) Parameter of MRG004A: Cmax
Maximum observed plasma concentration.
Pharmacokinetics (PK) Parameter of MRG004A: Tmax
Time to reach the maximum plasma concentration.
Pharmacokinetics (PK) Parameter of MRG004A: AUClast
Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration.
Incidence of anti-drug antibody (ADA)
The proportion of patients with positive ADA immunogenicity results.
Full Information
NCT ID
NCT04843709
First Posted
April 8, 2021
Last Updated
September 6, 2022
Sponsor
Shanghai Miracogen Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04843709
Brief Title
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Official Title
An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 26, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
June 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Miracogen Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
Detailed Description
This study consists of two parts. Part A is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG004A. Part B is a disease specific multi-cohort dose expansion study to further assess the efficacy and safety of MRG004A at confirmed RP2D.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced or Metastatic Solid Tumors
Keywords
MRG004A, Antibody drug conjugate (ADC), Tissue factor, Solid tumors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
181 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MRG004A
Arm Type
Experimental
Arm Description
All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
Intervention Type
Drug
Intervention Name(s)
MRG004A
Intervention Description
Administrated intravenously
Primary Outcome Measure Information:
Title
Maximum Tolerated Dose (MTD)
Description
The highest dose confirmed wherein less than 2 out of 6, or < 33% of evaluable patients in a treatment cohort experiences dose-limiting toxicity (DLT).
Time Frame
DLT will be evaluated during the first treatment cycle (Day 1-21)
Title
Recommended Phase II Dose (RP2D)
Description
The dose level of MRG004A recommended for further clinical studies based on assessment of the safety, efficacy and PK data from Part A of this study.
Time Frame
Baseline to study completion (up to 24 months)
Title
Objective Response Rate (ORR)
Description
The proportion of patients who achieve complete response (CR) or partial response (PR) as assessed by the Independent Central Review (ICR).
Time Frame
Baseline to study completion (up to 24 months)
Title
Adverse Events (AEs)
Description
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
Time Frame
From signing informed consent until 45 days after the last dose of MRG004A
Secondary Outcome Measure Information:
Title
Duration of Response (DoR)
Description
The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.
Time Frame
Baseline to study completion (up to 24 months)
Title
Disease Control Rate (DCR)
Description
The proportion of patients who achieve CR, PR, or stable disease (SD) ≥ 6 weeks based on RECIST v1.1.
Time Frame
Baseline to study completion (up to 24 months)
Title
Progression Free Survival (PFS)
Description
The time from the date of first study dose to disease progression or death whichever occurs first.
Time Frame
Baseline to study completion (up to 24 months)
Title
Overall Survive (OS)
Description
The time from start of study treatment to date of death as a result of any cause.
Time Frame
Baseline to study completion (up to 24 months)
Title
Pharmacokinetics (PK) Parameter of MRG004A: Cmax
Description
Maximum observed plasma concentration.
Time Frame
Baseline to 30 days after the last dose of study treatment
Title
Pharmacokinetics (PK) Parameter of MRG004A: Tmax
Description
Time to reach the maximum plasma concentration.
Time Frame
Baseline to 30 days after the last dose of study treatment
Title
Pharmacokinetics (PK) Parameter of MRG004A: AUClast
Description
Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration.
Time Frame
Baseline to 30 days after the last dose of study treatment
Title
Incidence of anti-drug antibody (ADA)
Description
The proportion of patients with positive ADA immunogenicity results.
Time Frame
Baseline to 30 days after the last dose of study treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Understands and provides written informed consent and willing to follow the requirements specified in protocol.
Age ≥18 years.
Life expectancy ≥6 months.
For Part B patients, documented Tissue Factor (TF) presence in tumor biopsy specimens obtained from archival or re-biopsy specimens by immunohistochemistry (IHC) protein expression.
Must have histologically or cytologically confirmed unresectable or metastatic cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types- Part A and Part B.
Part B: Patients who have documented progression during or relapse following standard therapy, no further treatment options that are known to improve survival, and participation in a clinical trial is a reasonable therapeutic option.
Patients must have measurable disease per RECIST v1.1.
ECOG performance status of 0 or 1.
Acceptable bone marrow, hepatic, cardiac, renal, and coagulation function.
A negative serum pregnancy test if female and aged between 18-55 years old.
Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 180 days after the last infusion of MRG004A.
Exclusion Criteria:
Archival or biopsy tumor shows TF IHC membrane or cytosolic score of zero, no TF-positive expression or no TF-positive staining in Part B patients.
Toxicities (except alopecia & fatigue) due to prior antitumor therapy are greater than CTCAE v5.0 Grade 1.
Toxicities due to prior radiotherapy that have not resolved to Grade ≤ 1 CTCAE v5.0 at least 21 days prior to the first treatment.
Untreated, unstable or uncontrolled central nervous system (CNS) metastases.
Any other type of anti-cancer therapy within 21 days of the first dose of study treatment. Use of any other type of anti-cancer treatment is prohibited throughout the study.
Patients with increased bleeding risk.
Presence of severe cardiac dysfunction.
Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.
Concurrent malignancy within 5 years prior to entry.
Uncontrolled or poorly controlled hypertension.
History of ventricular tachycardia, or torsade des pointes.
History of moderate to severe dyspnea at rest.
Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
Known allergic reactions to any component or excipient of MRG004A or known allergic reactions to other prior anti-TF (including investigational) or other monoclonal antibody ≥ Grade 3.
Patients who have any known liver disease, including chronic hepatitis B, hepatitis C, autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis; Patients who have concurrent, serious, uncontrolled infections or known infection with HIV, or have a diagnosed acquired immunodeficiency syndrome (AIDS); or an uncontrolled autoimmune disease, or have undergone organ transplant.
Active uncontrolled bacterial, viral, fungal, rickettsial, or parasitic infection.
Use of systemic corticosteroids within 4 weeks prior to the first dose of treatment.
Use of strong CYP3A4 inhibitors or inducers with MRG004A.
Other excluded medications or treatment: therapeutic anti-coagulative, or long-term anti-platelet treatment; multivitamins, calcium, vitamin D, and prophylactic anti-RANKL (denosumab) and zoledronic acid therapies for bone metastases are allowed.
Any patient with a positive pregnancy or is breast-feeding.
Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jenny Li
Phone
650-237-9339
Email
clinicaltrials@miracogen.com.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Leanne Drummond, Bachelor
Phone
984-208-9519
Email
leanne.drummond@worldwide.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nashat Y Gabrail, MD
Organizational Affiliation
Gabrail Cancer Center Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chao Family Comprehensive Cancer Center
City
Orange
State/Province
California
ZIP/Postal Code
92868-3201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carmen Lu
Email
ucstudy@hs.uci.edu
Facility Name
Memorial Sloan Kettering 60th Street Outpatient Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amin Yaqubie
Email
yaqubiea@mskcc.org
Facility Name
Gabrail Cancer Center Research
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nashat Y Gabrail, MD
Phone
330-492-3345
Email
ngabrailmd@gabrailcancercenter.com
First Name & Middle Initial & Last Name & Degree
Carrie Smith
Phone
330-492-3345
Ext
208
Email
csmith@gabrailcancercenter.com
Facility Name
The Christ Hospital Cancer Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abby Reed
Email
abby.reed@thechristhospital.com
Facility Name
Gettysburg Cancer Center
City
Gettysburg
State/Province
Pennsylvania
ZIP/Postal Code
17325
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Nocera
Email
christine@gettysburgoncology.com
Facility Name
Virginia Cancer Specialists
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcy Sullivan, RN, BSN, OCN
Phone
703-208-9268
Email
Marcy.Sullivan@usoncology.com
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Tang, M.D.
Phone
86-15274836636
Email
tangjie@hnca.org.cn
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
201321
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian Zhang, M.D
Phone
86-18017312991
Email
Syner2000@163.com
First Name & Middle Initial & Last Name & Degree
Xiaohua Wu, M.D
Phone
86-21-64175590
Ext
81006
Email
wu.xh@fudan.edu.cn
Facility Name
The First Affiliated Hospital, College of Medicine, Zhejiang University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianzhen Shan, M.D.
Phone
86-13757128607
Email
jianzhenshan@163.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
We'll reach out to this number within 24 hrs